Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O60701

UPID:
UGDH_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
O60701; B3KUU2; B4DN25; O60589

BACKGROUND:
The enzyme UDP-glucose 6-dehydrogenase is crucial for the formation of UDP-alpha-D-glucuronate, a key precursor in the biosynthesis of glycosaminoglycans such as chondroitin sulfate and heparan sulfate. These substances are essential for various biological processes, including embryonic development and neuronal function. The enzyme's role in converting glucose to glucuronate underscores its importance in cellular metabolism and development.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of UDP-glucose 6-dehydrogenase could open doors to potential therapeutic strategies for Developmental and epileptic encephalopathy 84. This condition, characterized by severe early-onset epilepsies and cognitive delays, highlights the enzyme's significance in neurological health and disease. Exploring its therapeutic targeting offers a promising avenue for addressing this challenging disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.